Jakarta, December 10, 2024 – PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has obtained marketing authorization for two innovative cancer therapies, Tislelizumab (ETAPIDI®) and Zanubrutinib (BRUKINSA®). Developed by BeiGene, which plans to change its name to BeOne Medicines, a global oncology leader committed to making cutting-edge and accessible treatments available worldwide, these therapies are set to transform cancer care in Indonesia by combining global advancements with local accessibility.

Read More

Jakarta, 14 November 2024 – PT Etana Biotechnologies Indonesia (Etana), a local Indonesian biopharmaceutical company and Celltrion, a leading global biopharmaceutical company specialized in researching, developing and manufacturing innovative therapeutics medicine, today announced that the companies have entered a strategic distribution and marketing agreement for Herzuma® (trastuzumab) and Truxima® (rituximab). These two treatments are first-line targeted therapies for breast cancer and non-Hodgkin's lymphoma, and listed in the National Formulary (Fornas) and e-catalogue.

Read More

Jakarta, 29 January 2024 – PT Etana Biotechnologies Indonesia (Etana) a local Indonesian biopharmaceutical company has entered a strategic collaboration with BeiGene, a global, science-driven biotechnology company. Nathan Tirtana, President Director of Etana together with Adam Roach BeiGene’s Vice President, and Head of Asia-Pacific, has committed to cooperate for the commercialization, development, and technology transfer of the Tislelizumab product.

Read More

Jakarta, 25 October 2023 – PT Etana Biotechnologies Indonesia (Etana), an indigenous Indonesian biopharmaceutical company, today received a visit from the Head of the Food and Drug Supervisory Agency (BPOM) to review the readiness of the production facility for raw materials for mRNA vaccines and multi-product filling facilities.  Concurrently during the visit, they also handed over the approval for distribution permits and approval for the implementation of clinical trials for the PCV13 vaccine product that will be produced by Etana.

Read More

Jakarta, 18 October 2023 – PT Etana Biotechnologies Indonesia (Etana), a biopharmaceutical company from Indonesia, has entered into a strategic collaboration with CanSino Biologics Inc (CanSinoBIO) at the Indonesia-People's Republic of China (PRC) Business Forum that was held at China World Hotel, Beijing, PRC, on Monday, October 16, 2023. This forum was held to commemorate the 10th anniversary of the Belt and Road Initiative (BRI), as well as to encourage joint development between the two countries.

Read More

Jakarta, 22 September 2023 – PT Etana Biotechnologies Indonesia (Etana), an indigenous Indonesian biopharmaceutical company which is the first company in ASEAN to have an mRNA technology platform, collaborates with the National Research and Innovation Agency (BRIN) and the University of New South Wales (UNSW) Australia in the development of research and innovation in the health sector, particularly in mRNA technology.

Read More